Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Rituximab, Bendamustine Look Better Than Chemo Alone in MCL

Key clinical point: In older patients with mantle cell lymphoma (MCL), first-line therapy with rituximab- and bendamustine-based regimens significantly reduced mortality rates versus chemotherapy alone.

Major finding: One-year MCL-specific mortality rates were better for patients receiving rituximab- and bendamustine-based regimens, compared with those receiving chemotherapy alone (hazard ratios, 0.38 and 0.49, respectively).

Study details: A retrospective analysis of 1,215 patients over age 65 years with newly diagnosed MCL.

Disclosures: The study was funded by the Duncan Family Institute, the Cancer Prevention Research Institute of Texas, and the National Institutes of Health. The authors reported having no conflicts of interest.

Citation:

Fu S et al. Clin Lymphoma Myeloma Leuk. 2019 Aug 30. doi: 10.1016/j.clml.2019.08.014.